Against the backdrop of continuous advancement in the global rare disease treatment landscape, the management of spinal muscular atrophy (SMA) has gradually transitioned from an untreatable condition to a disease that can now be actively intervened in and managed long term.

However, the rapid progress in therapeutic development has not been fully translated into equitable global access.

Significant disparities remain across countries and healthcare systems in patients’ ability to obtain innovative therapies.

As a global pharmaceutical distributor with long-standing focus on global drug distribution and rare disease treatment accessibility, DengYueMed observes a core contradiction: SMA therapies are globally advanced, yet access remains highly uneven.

SMA Treatment Landscape: From Supportive Care to Disease Modification

Historically, SMA management relied primarily on supportive care, including respiratory support, nutritional management, and physical rehabilitation.

With deeper understanding of disease mechanisms—particularly SMN1 gene deletion leading to progressive motor neuron degeneration—targeted therapies have emerged, enabling true disease modification.

Current major therapeutic approaches include:

1.  Antisense oligonucleotide (ASO) therapy: such as    nusinersen, which modulates SMN2 splicing to increase functional SMN protein production

2.  Oral small-molecule therapy: such as      risdiplam, offering systemic distribution and broad tissue exposure

3.  Gene replacement therapy: such as onasemnogene abeparvovec (    Zolgensma), a one-time treatment designed to enable long-term SMN protein expression

These therapies have significantly altered the natural history of SMA and made early diagnosis and early treatment critical determinants of clinical outcomes.

Global Treatment Accessibility: A Highly Uneven Reality

Despite therapeutic advances, global access to SMA treatment remains clearly stratified.

1. High-income countries: relatively high access but reimbursement-dependent

In the United States, parts of Europe, and Japan:

● Multiple treatment options are generally available

● Newborn screening programs are increasingly implemented

● However, high-cost therapies rely heavily on insurance coverage or special funding programs

● Access to gene therapies such as Zolgensma remains constrained by reimbursement policies

2. Middle-income countries: limited access with significant regional disparities

In parts of Asia and Latin America:

● Nusinersen and risdiplam have been introduced in some markets

● However, access is often concentrated in major urban medical centers

● Gene therapy remains largely inaccessible

● Insurance reimbursement levels are inconsistent and often insufficient

3. Low-income countries: persistent treatment gaps

In many regions of Africa and other developing areas:

● SMA diagnosis rates remain low

● Basic diagnostic capacity is limited

● Innovative disease-modifying therapies are largely unavailable

● Patients primarily rely on supportive care

Key Drivers of Limited Access: Multi-System Barriers

The accessibility challenges in SMA treatment are not driven by a single factor but rather by multiple systemic barriers.

The most prominent factor is the high cost of therapy. Gene therapies involve extremely high one-time costs, while chronic disease-modifying treatments accumulate substantial long-term expenses, placing significant pressure on healthcare budgets.

In addition, disparities in healthcare infrastructure further amplify inequities. Limited newborn screening coverage leads to delayed diagnosis, while specialized neuromuscular care resources are concentrated in a small number of centers.

Regulatory and supply chain differences also play a major role. Variations in approval timelines across countries, combined with inconsistent cold-chain logistics and specialty drug distribution systems, result in uneven global availability.

These factors collectively create a situation in which therapies may exist but remain inaccessible.

Global Trends: Gradual Improvement in Accessibility

Despite ongoing challenges, global SMA treatment accessibility is gradually improving.

First, newborn screening programs are expanding worldwide, enabling earlier diagnosis and significantly improving long-term outcomes.

Second, several countries are introducing innovative reimbursement models, such as installment-based payment systems and outcomes-based agreements, to reduce the financial burden of high-cost one-time therapies.

In parallel, international rare disease cooperation programs are expanding, enabling patients in some low- and middle-income countries to access therapies through special access pathways.

From a supply chain perspective, improvements in cold-chain logistics and cross-border pharmaceutical distribution are enhancing the global flow of innovative medicines.

From Innovation to Access: The Role of Global Distribution Systems

In the SMA treatment ecosystem, research and development is only the starting point. The true determinant of patient benefit lies in whether therapies can be reliably, sustainably, and compliantly delivered to healthcare systems worldwide.

This process involves multiple critical components, including:

● Cross-border logistics and cold-chain management to ensure product stability

● Regulatory coordination across countries to accelerate market access

● Regional inventory and distribution network optimization to reduce supply disruptions

● Integration with multi-level healthcare systems to improve end-user delivery efficiency

In this context, global pharmaceutical distribution systems serve as a vital bridge connecting innovation and patients.

As a global pharmaceutical distributor, DengYueMed continuously monitors the global flow of rare disease therapies. We believe the future challenge is not only to develop more therapies, but to build a more efficient, equitable, and sustainable global supply network that enables innovations to transcend geographic and systemic boundaries.

Conclusion: Equity and Accessibility as the Next Core Challenge

The evolution of SMA treatment demonstrates that modern medicine can profoundly alter the natural course of rare neuromuscular diseases. However, global treatment equity remains unachieved.

The central challenge ahead is no longer solely medical innovation, but ensuring that innovation translates into real-world access for patients worldwide. Only when therapies can cross economic, geographic, and systemic barriers can the full value of SMA treatment be realized.

DengYueMed will continue to monitor this transformation and support the optimization of global supply chain systems. We believe that improved coordination across distribution networks, healthcare systems, and policy frameworks will ultimately move SMA treatment toward more equitable global access.

For further reading on SMA mechanisms and clinical advances, see: Advances in Spinal Muscular Atrophy: Treatment, Research, and Comprehensive Management